Techtarget (TTGT) Shareholder Granahan Investment Management Has Lifted Its Position by $5.02 Million as Valuation Declined; As Abbvie (ABBV) Share Value Declined, Shareholder Tealwood Asset Management Trimmed by $375,248 Its Position

AbbVie Inc. (NYSE:ABBV) Logo

Tealwood Asset Management Inc decreased its stake in Abbvie Inc (ABBV) by 4.11% based on its latest 2018Q3 regulatory filing with the SEC. Tealwood Asset Management Inc sold 3,992 shares as the company’s stock declined 6.62% with the market. The institutional investor held 93,168 shares of the major pharmaceuticals company at the end of 2018Q3, valued at $8.81M, down from 97,160 at the end of the previous reported quarter. Tealwood Asset Management Inc who had been investing in Abbvie Inc for a number of months, seems to be less bullish one the $132.28B market cap company. The stock decreased 0.29% or $0.26 during the last trading session, reaching $87.94. About 2.69 million shares traded. AbbVie Inc. (NYSE:ABBV) has declined 7.04% since January 11, 2018 and is downtrending. It has underperformed by 7.04% the S&P500. Some Historical ABBV News: 15/03/2018 – Dynavax Announces Acceptance of Two Data Abstracts for SD-101 in Combination with KEYTRUDA® for Presentation at the 2018 Ameri; 05/04/2018 – Biogen, Samsung Bioepis in Settlement With AbbVie on Humira Biosimilar in Europe; 13/03/2018 – ABBVIE INC – RESULTS WERE CONSISTENT WITH FIRST PHASE 3 STUDY; 24/03/2018 – lmmunoGen Presents Data from FORWARD Il Assessment of Mirvetuximab Soravtansine in Combination with Pembrolizumab at the Society of Gynecologic Oncology Annual Meeting; 13/03/2018 – FDA Grants Priority Review to Merck’s Supplemental Biologics License Application (SBLA) for KEYTRUDA(R) (pembrolizumab) for Treatment of Advanced Cervical Cancer; 09/04/2018 – AbbVie’s promised rheumatoid arthritis blockbuster upadacitinib hits its marks in another PhIII – this time without any deaths $ABBV; 22/03/2018 – BerGenBio ASA: BerGenBio to present overview of phase II clinical trial portfolio combining bemcentinib with KEYTRUDA at 3rd Annual Immuno-Oncology Summit Europe; 21/05/2018 – AbbVie Presenting at UBS Conference Tomorrow; 09/04/2018 – Keytruda is already approved to treat several forms of cancer, including advanced melanoma. The drug racked up $3.81 billion in revenue in 2017; 16/04/2018 – BIOTHERA PHARMACEUTICALS PRESENTS TRANSLATIONAL DATA FROM ONGOING CLINICAL TRIALS SHOWING IMPRIME PGG IN COMBINATION WITH MERCK’S KEYTRUDA® (PEMBROLIZUMAB) DRIVES INNATE AND ADAPTIVE IMMUNE…

Granahan Investment Management Inc increased its stake in Techtarget Inc (TTGT) by 56.25% based on its latest 2018Q3 regulatory filing with the SEC. Granahan Investment Management Inc bought 263,968 shares as the company’s stock declined 39.10% with the market. The hedge fund held 733,238 shares of the miscellaneous company at the end of 2018Q3, valued at $14.24 million, up from 469,270 at the end of the previous reported quarter. Granahan Investment Management Inc who had been investing in Techtarget Inc for a number of months, seems to be bullish on the $356.46 million market cap company. The stock increased 0.95% or $0.12 during the last trading session, reaching $12.73. About 100,310 shares traded. TechTarget, Inc. (NASDAQ:TTGT) has declined 2.74% since January 11, 2018 and is downtrending. It has underperformed by 2.74% the S&P500. Some Historical TTGT News: 14/05/2018 – Granahan Investment Buys New 1.7% Position in TechTarget; 12/04/2018 – Google Named Official Cloud Sponsor of Actifio’s Data Driven 2018 Conference; 03/05/2018 – TechTarget Revolutionizes Account-Based Marketing (ABM) and Sales Productivity with Latest Release of Priority Engine Purchase Intent Platform; 04/05/2018 – River Road Asset Management LLC Exits Position in TechTarget; 10/05/2018 – TechTarget’s SearchVirtualDesktop.com Announces “Best of Citrix Synergy” 2018 Award Winners; 14/05/2018 – Ariel Investments LLC Exits Position in TechTarget; 09/05/2018 – TECHTARGET INC TTGT.O SEES FY 2018 REVENUE $122 MLN TO $124 MLN; 06/03/2018 – TechTarget’s SearchVirtualDesktop.com Announces Call for Nominations for Best of Citrix Synergy 2018 Awards; 09/05/2018 – TECHTARGET INC TTGT.O FY2018 REV VIEW $122.6 MLN — THOMSON REUTERS l/B/E/S; 15/05/2018 – Ashford Capital Management Buys New 1.3% Position in TechTarget

Granahan Investment Management Inc, which manages about $3.81 billion and $1.84B US Long portfolio, decreased its stake in Cyberark Software (NASDAQ:CYBR) by 6,259 shares to 48,362 shares, valued at $3.86 million in 2018Q3, according to the filing. It also reduced its holding in Zagg Inc (NASDAQ:ZAGG) by 47,759 shares in the quarter, leaving it with 85,142 shares, and cut its stake in Kornit Digital.

More notable recent TechTarget, Inc. (NASDAQ:TTGT) news were published by: Seekingalpha.com which released: “TechTarget Is Fundamentally Sound – Seeking Alpha” on November 28, 2018, also Seekingalpha.com with their article: “TechTarget May Be Outrunning Its Story – Seeking Alpha” published on February 20, 2018, Seekingalpha.com published: “TechTarget -4.6% as Q3 earnings growth lags expectations – Seeking Alpha” on November 07, 2018. More interesting news about TechTarget, Inc. (NASDAQ:TTGT) were released by: Seekingalpha.com and their article: “TechTarget, Inc. (TTGT) CEO Mike Cotoia on Q2 2018 Results – Earnings Call Transcript – Seeking Alpha” published on August 11, 2018 as well as Seekingalpha.com‘s news article titled: “TTGT +4%, FBC +1.8% on moves to SmallCap 600 – Seeking Alpha” with publication date: October 18, 2018.

Investors sentiment decreased to 2.18 in 2018 Q3. Its down 0.39, from 2.57 in 2018Q2. It dived, as 18 investors sold TTGT shares while 21 reduced holdings. 39 funds opened positions while 46 raised stakes. 16.98 million shares or 34.51% more from 12.62 million shares in 2018Q2 were reported. Millennium Management Ltd Liability Com owns 36,710 shares for 0% of their portfolio. Vanguard Gru reported 0% stake. Merian Glob Investors (Uk) invested in 0.01% or 107,510 shares. Marathon Management has invested 0.42% in TechTarget, Inc. (NASDAQ:TTGT). Moreover, Bankshares Of America De has 0% invested in TechTarget, Inc. (NASDAQ:TTGT). Gotham Asset Mgmt Lc owns 71,235 shares or 0.02% of their US portfolio. Lazard Asset Mgmt Lc has 0% invested in TechTarget, Inc. (NASDAQ:TTGT). Valley Natl Advisers owns 150 shares or 0% of their US portfolio. Prelude Mgmt Limited Liability Com accumulated 2,900 shares or 0% of the stock. National Bank & Trust Of Montreal Can stated it has 0% of its portfolio in TechTarget, Inc. (NASDAQ:TTGT). Massachusetts-based Wellington Gp Llp has invested 0% in TechTarget, Inc. (NASDAQ:TTGT). Citadel Ltd Llc has 380,907 shares. Tci Wealth Advsr holds 0% of its portfolio in TechTarget, Inc. (NASDAQ:TTGT) for 34 shares. 50,386 were accumulated by Timpani Mgmt Limited Liability. Great West Life Assurance Can invested 0% in TechTarget, Inc. (NASDAQ:TTGT).

Among 6 analysts covering TechTarget (NASDAQ:TTGT), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. TechTarget had 19 analyst reports since August 7, 2015 according to SRatingsIntel. The rating was maintained by Needham with “Buy” on Thursday, February 11. The rating was upgraded by TheStreet on Friday, August 7 to “Hold”. Jefferies maintained the shares of TTGT in report on Thursday, September 28 with “Hold” rating. The stock of TechTarget, Inc. (NASDAQ:TTGT) has “Hold” rating given on Wednesday, February 7 by Jefferies. On Wednesday, August 10 the stock rating was downgraded by Craig Hallum to “Hold”. Lake Street maintained TechTarget, Inc. (NASDAQ:TTGT) rating on Thursday, November 10. Lake Street has “Buy” rating and $9 target. The company was maintained on Wednesday, June 21 by Jefferies. The rating was initiated by Sidoti on Wednesday, July 20 with “Buy”. Craig Hallum maintained TechTarget, Inc. (NASDAQ:TTGT) rating on Thursday, May 10. Craig Hallum has “Buy” rating and $2500 target. The rating was maintained by Needham with “Buy” on Friday, January 12.

Since July 16, 2018, it had 0 insider purchases, and 26 insider sales for $22.19 million activity. The insider Strakosch Greg sold $473,000. Hawk Don also sold $282,488 worth of TechTarget, Inc. (NASDAQ:TTGT) shares. Levenson Bruce had sold 45,000 shares worth $914,625 on Thursday, September 13. Cotoia Michael also sold $488,750 worth of TechTarget, Inc. (NASDAQ:TTGT) shares. 2,000 shares valued at $62,040 were sold by Noreck Daniel T on Monday, July 16.

Since August 17, 2018, it had 0 insider purchases, and 6 insider sales for $26.66 million activity. Schumacher Laura J sold $2.25 million worth of AbbVie Inc. (NYSE:ABBV) on Friday, December 28. CHASE WILLIAM J also sold $5.40M worth of AbbVie Inc. (NYSE:ABBV) on Wednesday, December 12. Another trade for 42,450 shares valued at $3.82 million was made by Gosebruch Henry O on Thursday, November 29. SEVERINO MICHAEL also sold $4.88M worth of AbbVie Inc. (NYSE:ABBV) on Friday, August 17.

Among 26 analysts covering Abbvie Inc (NYSE:ABBV), 10 have Buy rating, 3 Sell and 13 Hold. Therefore 38% are positive. Abbvie Inc had 105 analyst reports since July 21, 2015 according to SRatingsIntel. The firm earned “Hold” rating on Sunday, July 30 by BMO Capital Markets. Bank of America maintained the stock with “Buy” rating in Wednesday, August 22 report. The stock of AbbVie Inc. (NYSE:ABBV) earned “Neutral” rating by UBS on Monday, September 25. The rating was maintained by Bank of America with “Buy” on Monday, July 30. The rating was maintained by BMO Capital Markets with “Hold” on Wednesday, October 11. The stock of AbbVie Inc. (NYSE:ABBV) earned “Buy” rating by Leerink Swann on Tuesday, December 5. The stock of AbbVie Inc. (NYSE:ABBV) has “Buy” rating given on Monday, May 29 by Jefferies. UBS maintained AbbVie Inc. (NYSE:ABBV) on Friday, October 13 with “Neutral” rating. Jefferies upgraded the stock to “Buy” rating in Monday, December 7 report. Piper Jaffray maintained the stock with “Buy” rating in Friday, September 15 report.

Analysts await AbbVie Inc. (NYSE:ABBV) to report earnings on January, 25 before the open. They expect $1.92 earnings per share, up 29.73% or $0.44 from last year’s $1.48 per share. ABBV’s profit will be $2.89 billion for 11.45 P/E if the $1.92 EPS becomes a reality. After $2.14 actual earnings per share reported by AbbVie Inc. for the previous quarter, Wall Street now forecasts -10.28% negative EPS growth.

Investors sentiment decreased to 0.82 in Q3 2018. Its down 0.12, from 0.94 in 2018Q2. It fall, as 60 investors sold ABBV shares while 637 reduced holdings. 107 funds opened positions while 466 raised stakes. 994.12 million shares or 0.91% less from 1.00 billion shares in 2018Q2 were reported. Maryland Capital Mngmt invested in 0.61% or 49,629 shares. Canada Pension Plan Invest Board accumulated 2.56 million shares or 0.45% of the stock. Company Bank, Missouri-based fund reported 320,561 shares. Northstar Inv Advsrs Limited Company reported 11,843 shares. Parsons Cap Mgmt Ri accumulated 80,315 shares or 0.8% of the stock. Partnervest Advisory Ltd has invested 0.35% in AbbVie Inc. (NYSE:ABBV). Moreover, Palouse Cap Management has 2.16% invested in AbbVie Inc. (NYSE:ABBV). 3.47M were reported by Aristotle Capital Mgmt Ltd Co. Rothschild Asset Us Inc owns 0.46% invested in AbbVie Inc. (NYSE:ABBV) for 474,385 shares. Arete Wealth Advsr Limited Liability Com invested in 13,618 shares or 0.29% of the stock. Valley National Advisers Inc owns 0.39% invested in AbbVie Inc. (NYSE:ABBV) for 11,821 shares. First Midwest Comml Bank Division holds 1.38% or 108,521 shares in its portfolio. Ftb Advisors has 686 shares for 0.04% of their portfolio. Lsv Asset Mgmt has 0.89% invested in AbbVie Inc. (NYSE:ABBV). Caprock Group has invested 0.23% of its portfolio in AbbVie Inc. (NYSE:ABBV).

Tealwood Asset Management Inc, which manages about $381.25 million and $267.15 million US Long portfolio, upped its stake in Western Alliance Bancorp (NYSE:WAL) by 18,970 shares to 56,330 shares, valued at $3.21M in 2018Q3, according to the filing.

More notable recent AbbVie Inc. (NYSE:ABBV) news were published by: 247Wallst.com which released: “Major Pharma Sees Fading Short Interest – 24/7 Wall St.” on January 11, 2019, also Streetinsider.com with their article: “AbbVie (ABBV), Tizona Therapeutics Report Strategic Collaboration to Develop First-in-Class Immunotherapy for Cancer Targeting CD39 – StreetInsider.com” published on January 03, 2019, Seekingalpha.com published: “AbbVie – Stemcentrx Impairment, A Worrying Sign? – Seeking Alpha” on January 10, 2019. More interesting news about AbbVie Inc. (NYSE:ABBV) were released by: Fool.com and their article: “3 Big Reasons Why AbbVie Isn’t Worried About Humira – The Motley Fool” published on January 10, 2019 as well as Seekingalpha.com‘s news article titled: “AbbVie teams up with Voluntis in companion digital therapeutics – Seeking Alpha” with publication date: December 19, 2018.

TechTarget, Inc. (NASDAQ:TTGT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.